Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pravachol Exclusivity Ruling Adds Uncertainty For ANDA Filers, Counsel Says

Executive Summary

A court decision reinstating Teva's generic exclusivity rights for Pravachol will make it more difficult for ANDA filers to predict when a dismissed declaratory judgment action could trigger 180-day exclusivity, FDA Associate Chief Counsel Elizabeth Dickinson said Oct. 26
Advertisement

Related Content

Pravachol Exclusivity: Teva Wins By Winning– FDA Wins By Losing?
Pravachol Exclusivity: Teva Wins By Winning– FDA Wins By Losing?
Zocor Exclusivity: Ranbaxy Needs Quick Win In Suit Seeking Patent Re-Listing
Teva Loses Exclusivity On Generic Pravachol; Earlier Court Case Was Trigger
Teva Loses Exclusivity On Generic Pravachol; Earlier Court Case Was Trigger
Declaratory Judgment Ruling Will Add Uncertainty To Generic Launches
Dismissal Of Teva Suit Triggered Ticlopidine 180-Days, Appeals Court Rules

Topics

Advertisement
UsernamePublicRestriction

Register

PS046496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel